Torrent Pharma Eyes Shanti Ekambaram as Director

Torrent Pharmaceuticals Limited has initiated a postal ballot seeking shareholder approval for the appointment of Shanti Ekambaram as an Independent Director. Her proposed three-year term is slated to commence on July 30, 2026, contingent on a special resolution from company members.

This strategic decision aims to integrate Ms. Ekambaram’s extensive 39 years of experience in financial services and governance into the company’s leadership. Her expertise is expected to bolster Torrent Pharma’s compliance structures and overall strategic direction.

Understanding the Shareholder Approval Process

The postal ballot process aligns with Section 110 of the Companies Act, 2013, alongside Rules 20 and 22 of the Companies (Management and Administration) Rules, 2014. It also adheres to Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

• Resolution Type: Special Resolution is required for approval.
• Eligibility Cut-off Date: Shareholders registered by July 31, 2026, are eligible to vote.
• E-voting Period: Voting commences on August 8, 2026, at 9:00 AM (IST) and concludes on September 6, 2026, at 5:00 PM (IST).
• Scrutinizer: Rajesh Parekh & Co. has been appointed to oversee the process.
• Results Expected: The outcome will be announced on or before September 8, 2026.

Electronic notices have been disseminated to eligible shareholders whose email IDs were registered by the specified cut-off date, following Ministry of Corporate Affairs (MCA) circulars. Central Depository Services (India) Limited (CDSL) is managing the e-voting platform.

Shanti Ekambaram’s Extensive Financial Expertise

Ms. Ekambaram, aged 63, brings a distinguished career spanning nearly four decades in the financial services sector. A significant portion of this experience, 35 years, was spent at Kotak Mahindra Bank.

• Served as Deputy Managing Director and Whole-time Director at Kotak Mahindra Bank until 2025.
• Headed Kotak Mahindra Capital Company, where she pioneered India’s first book-building IPO.
• Her professional expertise encompasses digital banking, treasury operations, human resources, and internal audit.

She currently holds additional directorships at Havells India Limited, Kotak Securities Limited, and Kotak Mahindra Capital Company Limited. This breadth of experience highlights her deep understanding of corporate governance and financial markets.

Her Role and Remuneration at Torrent Pharmaceuticals

Upon shareholder confirmation, Ms. Ekambaram will assume key responsibilities within Torrent Pharmaceuticals. She is slated to join three crucial committees:

• The Audit Committee.
• The Securities Transfer and Stakeholders Relationship Committee.
• The Nomination and Remuneration Committee.

Notably, she is not subject to retirement by rotation under the Companies Act, 2013, reflecting her independent director status. She holds no shares in Torrent Pharmaceuticals Limited and has no familial ties to other directors or key managerial personnel.

Her interim appointment as an Additional Director began on July 30, 2026. During this period, she has attended one board meeting and received ₹1 lakh in sitting fees, with her future remuneration to be determined by resolutions passed by the members.